VivoSim Labs, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.3M
- Price
- $0.2019
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.18%
- Volume
- 357.6K
About
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Quick stats
Shares outstanding16.6M
Computed float14.7M
Float / shares88.9%
Cash runway (months)7.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001497253
Websitehttps://vivosim.ai
AI Summary
AI-generated1/9
minorbullishoperations update
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
VivoSim Labs unveiled new NAMkind™ benchmark data at EUROTOX 2026 in Vienna, showing its 3D human liver and intestinal platforms can predict drug toxicity across small molecules and complex modalities like Antibody-Drug Conjugates.
The NAMkind™ Liver platform ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine, supports up to 28-day liver spheroid viability, and the intestinal models maintain barrier integrity for up to three weeks, enabling repeat-dose testing that shorter assays miss.
Management framed the FDA's accelerating shift away from animal testing as a favorable backdrop for its predictive toxicology services, while explicitly noting the regulatory shift does not represent an endorsement of VivoSim specifically.
The presentation marks a validation point for the commercial thesis, but no new contracts, revenue figures, or adoption metrics were disclosed, so commercial traction remains unproven.
Red flags
- No new contracts, revenue figures, or commercial adoption metrics disclosed alongside the data
- Company itself cautions the FDA regulatory shift 'does not represent an endorsement of VivoSim specifically'
- Data is company-generated conference material, not independently validated or peer-reviewed